Markus Riederer - Idorsia VP Biology
| IDIA Stock | CHF 3.91 0.06 1.51% |
Insider
Markus Riederer is VP Biology of Idorsia
| Age | 61 |
| Address | Hegenheimermattweg 91, Allschwil, Switzerland, 4123 |
| Phone | 41 58 844 10 10 |
| Web | https://www.idorsia.com |
Idorsia Management Efficiency
The company has return on total asset (ROA) of (0.1599) % which means that it has lost $0.1599 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (64.6068) %, meaning that it generated substantial loss on money invested by shareholders. Idorsia's management efficiency ratios could be used to measure how well Idorsia manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 0.21 in 2026, whereas Return On Tangible Assets are likely to drop (0.66) in 2026. At this time, Idorsia's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 253.8 M in 2026, whereas Non Currrent Assets Other are likely to drop slightly above 8.6 M in 2026.Similar Executives
| Showing other executives | INSIDER Age | ||
| Giulio Evangelisti | COSMO Pharmaceuticals SA | 53 | |
| Daniel Lasanow | PolyPeptide Group AG | 61 | |
| Hazel Winchester | COSMO Pharmaceuticals SA | 52 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Lutz Wevelsiep | Basilea Pharmaceutica AG | N/A | |
| Ravi Anand | Newron Pharmaceuticals SpA | 66 | |
| Patrick Christ | Medartis Holding AG | 53 | |
| Mauro Ajani | COSMO Pharmaceuticals SA | 71 | |
| Alistair Irvine | Kuros Biosciences AG | 54 | |
| Anthony DurieuxMenage | Medartis Holding AG | 49 | |
| Michael Staheli | PolyPeptide Group AG | 61 | |
| Patrick Amstutz | Molecular Partners AG | 51 | |
| Davide Malavasi | COSMO Pharmaceuticals SA | 53 | |
| Jan Miller | PolyPeptide Group AG | 53 | |
| Neville MD | Santhera Pharmaceuticals Holdin | N/A | |
| Marco Caremi | Newron Pharmaceuticals SpA | 66 | |
| , MBA | Molecular Partners AG | 50 | |
| MS DO | Kuros Biosciences AG | N/A | |
| FCMA CGMA | Santhera Pharmaceuticals Holdin | 60 | |
| Biagio Vigano | COSMO Pharmaceuticals SA | 49 | |
Management Performance
| Return On Equity | -64.61 | ||||
| Return On Asset | -0.16 |
Idorsia Leadership Team
Elected by the shareholders, the Idorsia's board of directors comprises two types of representatives: Idorsia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Idorsia. The board's role is to monitor Idorsia's management team and ensure that shareholders' interests are well served. Idorsia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Idorsia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arno Groenewoud, Executive CFO | ||
| Andrew Jones, Head VP | ||
| Christoph Boss, Senior Chemistry | ||
| Martine Clozel, Ex Officer | ||
| Alexander Khatuntsev, Senior Resources | ||
| Andr Muller, Ex CFO | ||
| Markus Riederer, VP Biology | ||
| Simon Jose, Ex Officer | ||
| Andrew Weiss, Sr Communications | ||
| Olivier Lambert, Senior Operations | ||
| Alberto MD, Executive Affairs | ||
| JeanPaul MD, CEO Director | ||
| Julien LLM, Group VP | ||
| Andre Muller, Advisor | ||
| Guy MD, Ex Officer | ||
| Srishti MD, CEO Director |
Idorsia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Idorsia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -64.61 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.97) % | ||||
| Current Valuation | 2.18 B | ||||
| Shares Outstanding | 245.72 M | ||||
| Shares Owned By Insiders | 30.52 % | ||||
| Shares Owned By Institutions | 14.22 % | ||||
| Price To Book | 27.65 X | ||||
| Price To Sales | 4.23 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Idorsia Stock Analysis
When running Idorsia's price analysis, check to measure Idorsia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Idorsia is operating at the current time. Most of Idorsia's value examination focuses on studying past and present price action to predict the probability of Idorsia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Idorsia's price. Additionally, you may evaluate how the addition of Idorsia to your portfolios can decrease your overall portfolio volatility.